“…Recent advances in the synthesis of multisubstituted pyridines include transition metal-catalyzed intermolecular cyclization to access functionalized pyridine derivatives from pre-functionalized substrates. ,,, A variety of intermolecular cyclization methodologies have been developed to access tri-substituted pyridines, including [2+2+2], [2+2+1+1], [3+3], [3+2+1], and [4+2] cycloadditions and cycloisomerizations. ,,, A majority of the reported methodologies focus on the synthesis of 2,3,6-, 2,3,5-, and 2,4,6-trisubstituted pyridines with fewer methodologies focusing on 2,3,4- and 2,4,5-trisubstituted pyridines (Scheme ). ,,− Only a limited number of synthetic strategies are available to access 3,4,5-trisubstituted pyridines, making it a challenging substitution pattern, which is generally accessed with sequential cross-coupling reactions. ,− Diverse tri-substitution patterns of pyridines are found in a number of FDA-approved drugs such as etoricoxib (2,3,5-), lansoprazole (2,3,4-), and netupitant (2,4,5-) (Figure ). The development of a new, facile strategy to access the less explored pyridine substitution patterns from readily available substrates may enable the development of alternatively substituted pyridines for exploration in medicinal chemistry.…”